# Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

> **NCT03714958** · PHASE1 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 12 (actual)

## Conditions studied

- Colorectal Cancer
- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** HDM201
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03714958
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2023-09-12
- **Final completion:** 2023-09-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03714958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03714958, "Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03714958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*